208 related articles for article (PubMed ID: 36504589)
1. Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy.
Aldahlawi AM; Abdullah ST
J Microsc Ultrastruct; 2022; 10(3):107-113. PubMed ID: 36504589
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell therapy in cancer treatment; the state-of-the-art.
Sadeghzadeh M; Bornehdeli S; Mohahammadrezakhani H; Abolghasemi M; Poursaei E; Asadi M; Zafari V; Aghebati-Maleki L; Shanehbandi D
Life Sci; 2020 Aug; 254():117580. PubMed ID: 32205087
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation.
Steinman RM
Mt Sinai J Med; 2001 May; 68(3):160-6. PubMed ID: 11373688
[TBL] [Abstract][Full Text] [Related]
4. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
6. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
7. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
[TBL] [Abstract][Full Text] [Related]
8. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.
Bakdash G; Schreurs I; Schreibelt G; Tel J
Expert Rev Clin Immunol; 2014 Jul; 10(7):915-26. PubMed ID: 24758519
[TBL] [Abstract][Full Text] [Related]
10. DC-Based Vaccines for Cancer Immunotherapy.
Fu C; Zhou L; Mi QS; Jiang A
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33255895
[TBL] [Abstract][Full Text] [Related]
11. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells.
Utsugi-Kobukai S; Fujimaki H; Hotta C; Nakazawa M; Minami M
Immunol Lett; 2003 Oct; 89(2-3):125-31. PubMed ID: 14556969
[TBL] [Abstract][Full Text] [Related]
12. Viral vectors for dendritic cell-based immunotherapy.
Humrich J; Jenne L
Curr Top Microbiol Immunol; 2003; 276():241-59. PubMed ID: 12797451
[TBL] [Abstract][Full Text] [Related]
13. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
14. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
Foley R; Tozer R; Wan Y
Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
[TBL] [Abstract][Full Text] [Related]
15. Between biology and medicine: perspectives on the use of dendritic cells in anticancer therapy.
Szczygieł A; Pajtasz-Piasecka E
Postepy Hig Med Dosw (Online); 2017 Nov; 71(0):921-941. PubMed ID: 29176007
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.
Schreibelt G; Tel J; Sliepen KH; Benitez-Ribas D; Figdor CG; Adema GJ; de Vries IJ
Cancer Immunol Immunother; 2010 Oct; 59(10):1573-82. PubMed ID: 20204387
[TBL] [Abstract][Full Text] [Related]
18. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
19. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
20. [Development of effective antigen delivery carrier to dendritic cells via Fc receptor in cancer immunotherapy].
Suzuki R; Utoguchi N; Kawamura K; Kadowaki N; Okada N; Takizawa T; Uchiyama T; Maruyama K
Yakugaku Zasshi; 2007 Feb; 127(2):301-6. PubMed ID: 17268150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
